Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease (OPEN-HART)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )
ClinicalTrials.gov Identifier:
NCT01306929
First received: February 28, 2011
Last updated: April 10, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: May 2021
  Estimated Primary Completion Date: April 2021 (Final data collection date for primary outcome measure)